Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Breast Neoplasms 53Neoplasm Metastasis 16Carcinoma, Non-Small-Cell Lung 10Neoplasms 7Brain Neoplasms 5Prostatic Neoplasms 3Ovarian Neoplasms 3Neoplasms by Site 3Melanoma 3Glioma 3Endometrial Neoplasms 3Colorectal Neoplasms 3Breast Diseases 3Sarcoma, Ewing 2Recurrence 2Pancreatic Neoplasms 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma 2Glioblastoma 2Advanced Cancer 2Uterine Cervical Neoplasms 1Urogenital Neoplasms 1Unilateral Breast Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Spinal Cord Neoplasms 1Solid Tumor, Adult 1Sarcoma 1Rhabdomyosarcoma 1

Interventions

Nivolumab 19Ipilimumab 9linrodostat 6relatlimab 4Pemetrexed 4Paclitaxel 4Carboplatin 4ARRY-334543 4Docetaxel 3regorafenib 2anlotinib 2abemaciclib 2N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide 2Gemcitabine 2Cyclophosphamide 2Capecitabine 26-(6-(1-methyl-1H-pyrazol-4-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-ylsulfanyl)quinoline 2vorolanib 1trametinib 1tislelizumab 1sargramostim 1ralimetinib 1prexasertib 1palifosfamide lysine 1p38 Mitogen-Activated Protein Kinases 1mirdametinib 1lirilumab 1indibulin 1gedatolisib 1fluzoparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Advanced Cancer × abemaciclib × Clear all
NCT01394016 2024-09-19

A Phase 1 Study of LY2835219 In Participants With Advanced Cancer

Eli Lilly and Company

Phase 1 Completed
225 enrolled 31 charts

Advanced Cancer

NCT04071262 2021-09-21

A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Therapies in Japanese Participants With Advanced Cancer

Eli Lilly and Company

Phase 1 Completed
6 enrolled

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡